The ALOX12 Knockout HCT 116 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal knockout cell population in which the ALOX12 gene has been disrupted in the HCT 116 colorectal carcinoma cell line. This heterogeneous pool of gene-edited cells serves as a loss-of-function model for studying arachidonate 12-lipoxygenase, enabling investigation of its roles in cancer biology, inflammation, and lipid mediator signaling. The polyclonal format preserves population-level diversity and avoids artifacts associated with single-cell clonal expansion.
HCT 116 is a near-diploid human colon carcinoma cell line with epithelial morphology, derived from a male patient with colorectal adenocarcinoma. It is widely utilized in colorectal cancer research due to its well-characterized genetic background, including mutations in KRAS and ??-catenin, which drive constitutive activation of growth and survival pathways. This cell line is particularly suited for mechanistic studies of oncogenic signaling, drug response profiling, and functional genomics.
The ALOX12 gene encodes arachidonate 12-lipoxygenase, which catalyzes the oxygenation of arachidonic acid to 12-HPETE, rapidly reduced to 12-HETE. 12-HETE acts as a lipid mediator that binds and activates the BLT2 receptor, leading to downstream signaling through PI3K/AKT and NF-??B cascades. This signaling axis promotes the expression of key effectors such as BCL2, Cyclin D1, MMP9, and VEGF, which drive cell proliferation, survival, and metastasis. ALOX12 is transcriptionally regulated by RUNX1, GATA1, and SP1, and can be induced by IL-4, IL-13, EGF, and TGFB1. It functionally interacts with PLA2G4A, ALOX5, PTGS2, and GPX4, integrating with broader arachidonic acid metabolism and oxidative stress pathways.
Within the HCT 116 colorectal cancer context, ALOX12-catalyzed 12-HETE production has been associated with enhanced tumor growth and invasive capacity. Knockout of ALOX12 in this cell line can dissect its contributions to PI3K/AKT and NF-??B-mediated oncogenic phenotypes and its crosstalk with MAPK signaling. The polyclonal knockout cells allow assessment of ALOX12-dependent effects at the population level, providing a robust platform for functional studies without the bias of clonal variation.
This product supports a wide range of research applications, including colorectal cancer biology, lipid mediator function, arachidonic acid metabolism, and drug sensitivity screening. Compatible assays include Western blotting, RT-qPCR, 12-HETE ELISA, cell migration and colony formation assays, RNA-seq, lipidomic profiling, flow cytometric apoptosis analysis, and phospho-signaling antibody arrays. Researchers can employ these cells to explore the role of ALOX12 in tumor progression, inflammation, and platelet biology. For product inquiries or technical assistance, please contact Ascent Research.
